688506 Sichuan Biokin Pharmaceutical
- 183.02
- -1.97-1.06%
Sichuan Biokin Pharmaceutical News
Baili Tianheng (688506.SH): BL-B16D1 for injectable treatment of advanced solid tumors obtained approval notice for phase I clinical trials
Gelonghui, May 9丨Baili Tianheng (688506.SH) announced that the self-developed innovative biopharmaceutical BL-B16D1 (dual antibody ADC) recently received the “Drug Clinical Trial Approval Notice” officially approved and issued by the National Drug Administration (NMPA). BL-B16D1 is a dual anti-ADC drug independently developed by the company and conjugated to a new generation of toxins. Its indications are advanced solid tumors.
Sichuan Biokin Pharmaceutical Gets China Clinical Trial Nod for Cancer Drug
China's National Medical Products Administration granted clinical trial approval for Sichuan Biokin Pharmaceutical's (SHA:688506) BL-B01D1 anti-cancer injectable, according to a Tuesday filing with th
Solid Earnings Reflect Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Strength As A Business
Sichuan Biokin Pharmaceutical Co.,Ltd.'s (SHSE:688506) strong earnings report was rewarded with a positive stock price move. Our analysis found some more factors that we think are good for shareholde
Baili Tianheng (688506.SH): 2023 net profit - 780 million yuan
Gelonghui, April 26丨Baili Tianheng (688506.SH) released its 2023 annual report. During the reporting period, the company achieved operating revenue of 562 million yuan, a decrease of 20.11% over the same period last year. Net profit attributable to listed companies - $780 million, a decrease of 176.40% compared with the same period last year. The main reason was that phase III clinical trials continued to be invested in pre-clinical research and clinical trial research during the reporting period. As R&D progress continued to advance, R&D investment increased, leading to a continuous increase in the company's R&D expenses.
Sichuan Biokin Pharmaceutical Gets Approval to Trial Lung Cancer Drug
Sichuan Biokin Pharmaceutical (SHA:688506) will conduct clinical trials on BL-B01D1 for injection after receiving approval from China's National Medical Products Administration, according to the compa
Baili Tianheng (688506.SH): “BL-B01D1+PD-1 monoclonal antibody ± chemotherapy” for locally advanced or metastatic non-small cell lung cancer obtained approval notice for phase II clinical trials
Gelonghui, April 21丨Baili Tianheng (688506.SH) announced that the combination drug “BL-B01D1+PD-1 monoclonal antibody ± chemotherapy” related to the innovative biopharmaceutical injectable BL-B01D1 (EGFR×HER3-ADC) independently developed by the company recently received the “Drug Clinical Trial Approval Notice” officially approved and issued by the National Drug Administration (NMPA). BL-B01D1 is a globally exclusive clinical-stage dual-antibody ADC drug independently developed by the company that targets both EGFR and HER3. EGFR and/or HER3 are in most epithelium
Chinese Drug Regulator Puts Sichuan Biokin Pharmaceutical's Naxopharynx Cancer Drug in Breakthrough Drugs List
China's National Medical Products Administration included Sichuan Biokin Pharmaceutical's (SHA:688506) BL-B01D1 for injection in the list of breakthrough therapy drugs, according to the company's disc
Baili Tianheng (688506.SH): Injectable BL-B01D1 is used to treat terminal patients with locally advanced or metastatic nasopharyngeal cancer included in the list of breakthrough treatment varieties
Baili Tianheng (688506.SH) announced that the company's self-developed innovative biopharmaceutical injectable BL-B01D1...
Baili Tianheng (688506.SH): BL-B01D1 for injection completed the first case of recurrent or metastatic esophageal squamous cell carcinoma phase III clinical trial
Gelonghui, April 9 | Bailey Tianheng (688506.SH) announced that the self-developed innovative biopharmaceutical injectable BL-B01D1 (EGFR×HER3-ADC) is currently undergoing phase III clinical trials for recurrent or metastatic esophageal squamous cell carcinoma, and has recently successfully completed the first case of the subject.
Baili Tianheng (688506.SH): “BL-M07D1+PD-1/PD-L1 monoclonal antibody ± chemotherapy” and “BL-M07D1+ pertuzumab ± chemotherapy” obtained approval notice for phase II clinical trials
Gelonghui, April 2 | Baili Tianheng (688506.SH) announced that the combined drugs “BL-M07D1+PD-1/PD-L1 monoclonal antibody ± chemotherapy” and “BL-M07D1+ pertuzumab ± chemotherapy” related to the innovative biopharmaceutical BL-M07D1 developed by the company have recently received the “Drug Clinical Trial Approval Notice” officially approved and issued by the National Drug Administration (NMPA). BL-M07D1 is an ADC drug targeting HER2. Its indications are solid tumors such as breast cancer and stomach cancer.
OAP III (HK) Limited, the majority shareholder of Baili Tianheng (688506.SH), reduced its holdings by 1.38% through an inquiry and transfer
Baili Tianheng (688506.SH) issued an announcement. In this inquiry and transfer, the company's shareholder OAP III (...
Baili Tianheng (688506.SH): Preliminary confirmation of the transfer price of this inquiry is 109.25 yuan/share
Baili Tianheng (688506.SH) issued an announcement. According to the inquiry and subscription situation on March 22, 2024, preliminary...
Shareholder of Baili Tianheng (688506.SH) OAP III (HK) Limited plans to transfer 1.50% of the shares through an inquiry
Baili Tianheng (688506.SH) issued an announcement. The company's shareholder OAP III (HK) Lim...
Baili Tianheng (688506.SH): BL-M05D1 (ADC) for injectable treatment of locally advanced solid tumors obtained approval notice for phase I clinical trials
Baili Tianheng (688506.SH) issued an announcement. The innovative biopharmaceutical BL-M05D1 independently developed by the company (...
Baili Tianheng (688506.SH): Received US$800 million down payment for BL-B01D1 project
Zhitong Finance App News, Baili Tianheng (688506.SH) announced that on December 11, 2023, SysTimMune, Inc.'s wholly-owned subsidiary SysTimMune, Inc. and Bristol-Myers Squibb (“BMS”, NYSE code: BMY) reached an exclusive license and cooperation agreement for the BL-B01D1 (EGFR×HER3 dual-antibody ADC) project. On February 8, 2024, the cooperation agreement officially came into effect. As of March 7, 2024, the company has received an initial payment of 800 million US dollars from BMS (the actual payment amount is subject to bank charges). The company expects
Is Sichuan Biokin PharmaceuticalLtd (SHSE:688506) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Biokin Pharmaceutical's Loss Widens in 2023; Shares Rise 4%
Sichuan Biokin Pharmaceutical's (SHA:688506) net loss widened to 763.9 million yuan, or 1.90 yuan per share, in 2023, from 282.4 million yuan, or 0.78 yuan per share, in 2022, a Monday filing said. To
Baili Tianheng (688506.SH) Performance Report: Net loss of 764 million yuan in 2023
Gelonghui, Feb. 23 | Bailey Tianheng (688506.SH) announced its 2023 annual performance report. During the reporting period, the company achieved total operating revenue of 562 million yuan, a year-on-year decrease of 20.11%; realized net profit attributable to owners of the parent company - 764 million yuan, a year-on-year decrease of 48,1520,900 yuan; net profit attributable to owners of the parent company after deducting non-recurring profit and loss - 795 million yuan, a year-on-year decrease of 4,580.459 million yuan.
Biokin Pharma's Commercialization Deal With Bristol Myers Squibb for Cancer Drug Becomes Effective
Sichuan Biokin Pharmaceutical (SHA:688506) said its license agreement with Bristol Myers Squibb officially started on Feb. 8. The Chinese pharmaceutical company, through its US unit SystImmune, signed
Bailey Tianheng (688506.SH): The subsidiary and Bristol-Myers Squibb enter into force for the development and commercialization of BL-B01D1
Zhitong Finance App News, Bailey Tianheng (688506.SH) announced that on December 11, 2023, the board of directors of the company deliberated and passed the “Proposal on Reaching a Global Strategic Cooperation Agreement between Wholly-owned Subsidiary SystimMune and Bristol-Myers Squibb on BL-B01D1 Development and Commercialization Rights”. The board of directors agreed that the company's wholly-owned subsidiary Systimmune, Inc. (“SysTimmune”) and Bristol-Myers Squibb (“BMS”) reached an exclusive license and cooperation agreement (“Cooperation Agreement”) on the BL-B01D1 project ). Based on 1976's
Analysis
Price Target
No Data
